Interesting pivot from “proof of life” to entirely different questions 😶
Avoiding “road shows” during active MAA review is wise considering selective disclosure rules…
And you’re expecting insider buying during regulatory review while material non-public info might be emerging & floating around the office on any given day? LP already owns about 2% of NWBO & she’s holding her shares.
NWBO just acquired a valuable asset that LP built, & she has been positioning the company for growth & expansion with more than one pipeline product platform. NWBO’s technologies may become relevant components of COMBO therapy regimens for multiple oncology indications thanks to LP’s work involving Roswell in New York & Pitt (in addition to UCLA).
Market Data 
Markets 
AI
